Conferences

22
Apr

HypoSkin® presented at New Frontiers in 3D in Cambridge, MA

Genoskin presents its subcutaneous injection model HypoSkin® at New Frontiers in 3D Genoskin’s CEO Pascal Descargues, PhD will attend scientific symposium New Frontiers in 3D at the MIT Samberg Center in Cambridge, MA, USA. Take the opportunity to discover our unique subcutaneous injection model through a poster presentation.   Hyposkin®, a unique human skin model to study subcutaneous injection Poster
Read more
7
Mar

Unique subcutaneous injection model at SOT meeting in Baltimore

Genoskin presents unique subcutaneous injection model at SOT Baltimore The Genoskin team spreads its wings: in March, you'll find us at the Society of Toxicology's Annual Meeting in Baltimore, US, where we'll present our new HypoSkin model to test the efficacy and toxicity of subcutaneous injections on live human skin models.   Unique tools to test human skin response to all
Read more
2
Mar

DBV’s immunotherapy tested on Genoskin’s skin models

DBV Technologies' epicutaneous immunotherapy tested using NativeSkin® ex vivo human skin Latest results to be presented at the AAAAI/WAO Joint Congress in Orlando The poster "Epicutaneous immunotherapy with peanut directly targets Langerhans cells in human skin" (n° 723, session  4204) will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in Orlando, Florida on
Read more
14
Dec

Genoskin in Japan to attend 42th Annual JSID meeting

GENOSKIN TO ATTEND 42TH ANNUAL JSID MEETING Genoskin is very pleased to attend the 42th Annual Meeting of the Japanese Society for Investigative Dermatology (JSID). The meeting will take place in Kochi city, Japan from December 15th to 17th, 2017. The mission of the Japanese Society for Investigative Dermatology (JSID) is to advance the position of dermatology in the interdisciplinary world

Read more

29
Sep

Genoskin launches psoriasis skin model at ESDR-meeting

Toulouse, France, September 29th, 2017 – Genoskin launches a new skin model to study skin inflammation. InflammaSkin® is a T cell-driven skin inflammation model with a psoriasis-like phenotype. The pharmacological validation of this psoriasis skin model will be presented at the 47th annual ESDR meeting 2017 (Poster 100) on September 27th to 30th, 2017. Don't hesitate to visit us in booth #9. Why immunocompetent skin
Read more
13
Sep

Genoskin kicks off fundraising campaign

Genoskin kicks off fundraising campaign at CCI FINDays The Genoskin team is now officially ready to launch its biggest fundraising campaign so far, which aims to finance our international expansion. Pascal Descargues, our CEO, is heading for Paris next week to attend the CCI FINDays, the first in a series of fundraising meetings. CCI FINDays is a French event designed to help small and start-up
Read more